相关实验视频

Updated: Mar 14, 2026

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

德尔帕西巴特 (Delpacibart Etedesiran) 在MARINA®研究的1/2阶段改善了1型肌性发育不良的分子病理学

Tanya T Kwan¹, Qingying Meng¹, Nathaniel Delos Santos¹

¹Avidity Biosciences, A Novartis Company, 3020 Callan Rd, San Diego, CA, USA, 92121.

Molecular therapy : the journal of the American Society of Gene Therapy

|March 13, 2026

概括

德尔帕西巴特 (delpacibart etedesiran,del-desiran) 通过降低有毒的DMPKRNA和恢复MBNL蛋白水平,有效地治疗1型肌性缩症. 这种新疗法在改善肌肉功能和治疗神经肌肉疾病方面表现有前途.

科学领域:

遗传学和分子生物学
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

肌性缩症1型 (DM1) 是一种进展性神经肌肉疾病,是由DMPK基因中CTG重复扩张引起的.
这种扩张导致有毒的RNA聚合物,封存像MBNL这样的拼接因子,并导致异常的mRNA拼接,导致DM1病理.

研究的目的:

评估delpacibart etedesiran (del-desiran),一种抗体-寡核酸合物 (AOCTM) 的疗效,用于治疗DM1.
评估del-desiran向肌肉细胞传递向DMPK的小干扰RNA并纠正疾病机制的能力.

主要方法:

德尔-德西兰 (AOCTM) 的设计,用于通过转激素受体1向肌肉提供siRNA的向输送.
向临床前模型 (患者衍生的神经管,Cynomolgus) 给予del-desiran,并评估DMPK mRNA,MBNL水平和拼接.
肌肉功能改善与MBNL增加的相关性.

主要成果:

德尔 - 德西兰剂量依赖性降低突变DMPKmRNA表达.
观察到功能MBNL蛋白的水平增加.
疾病相关的错误拼接得到了纠正,肌肉功能改善的趋势与MBNL增加相关.

结论:

德尔-德西兰通过向有毒的DMPKRNA并恢复拼接因子水平,证明了治疗DM1的明确作用机制.
该药物的疗效从临床前模型转化为患者,支持其用于DM1的开发.
该AOCTM平台显示了治疗其他神经肌肉疾病的潜力.

更多相关视频

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

相关概念视频

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...